Rasgef1A is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| RASGEF1A | |
|---|---|
| Gene Symbol | RASGEF1A |
| Full Name | RasGEF Domain Family Member 1A |
| Chromosome | 10q21.3 |
| NCBI Gene ID | 54974 |
| OMIM | 607619 |
| Ensembl ID | ENSG00000165682 |
| UniProt ID | Q8IUR5 |
| Associated Diseases | Cancer, Neurodegeneration, Developmental Disorders |
RasGEF Domain Family Member 1A (RASGEF1A) is a member of the Ras guanine nucleotide exchange factor (RasGEF) family that catalyzes the exchange of GDP for GTP on Ras proteins, thereby activating Ras signaling pathways. Ras proteins are small GTPases that function as molecular switches controlling cell proliferation, differentiation, survival, and synaptic plasticity. Dysregulated Ras signaling contributes to cancer development and has been implicated in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). RASGEF1A is expressed in various tissues, with particular abundance in brain, and plays important roles in neuronal function and development.
RasGEF1A contains a conserved RasGEF domain that catalyzes the activation of Ras proteins by promoting the exchange of bound GDP for GTP. This activity is essential for:
The Ras family includes H-Ras, N-Ras, K-Ras4A, and K-Ras4B, all of which can be activated by RasGEF family members. Different GEFs show selectivity for specific Ras isoforms, influencing downstream pathway activation.
Activated Ras proteins recruit and activate RAF kinases (ARAF, BRAF, RAF1), which initiate the MAPK/ERK cascade:
This pathway regulates:
In neurons, Ras-MAPK signaling is critical for:
Ras-MAPK signaling drives cell cycle progression from G0/G1 to S phase. Dysregulated signaling can lead to:
RasGEF1A dysregulation contributes to oncogenesis through:
Multiple cancers show elevated RASGEF1A expression, including:
Alzheimer's Disease:
Parkinson's Disease:
Huntington's Disease:
Amyotrophic Lateral Sclerosis (ALS):
Rasopathies are developmental syndromes caused by Ras-MAPK pathway dysregulation:
While RASGEF1A is not typically mutated in these conditions, it participates in the same pathway.
RASGEF1A is expressed in various tissues:
In the brain, RASGEF1A is expressed in:
Expression is developmentally regulated, with highest levels during brain development.
Targeting Ras-MAPK pathway:
Modulating Ras-MAPK signaling:
The study of Rasgef1A has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.